InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash of NIS 43 Million

Core Insights - InterCure reported preliminary estimated revenue of NIS 265 million for 2025, marking an 11% increase compared to 2024, with nearly 20% revenue growth in the second half of 2025 compared to the same period in the previous year [1][5][6] - The company achieved positive Adjusted EBITDA for the twelfth consecutive half-year, indicating consistent operational profitability [1][5][6] - Significant revenue generation from the German market began in the second half of 2025, contributing to the company's global expansion strategy [1][6] Financial Performance - Estimated annual revenue for 2025 is NIS 265 million, with approximately NIS 135 million generated in the second half [5] - Cash on hand as of December 31, 2025, was NIS 43 million [5] - The company resumed production and sales from the Nir Oz facility after disruptions due to the October 7, 2023 attack [5] Strategic Developments - InterCure launched over 70 new GMP SKUs in 2025, establishing category-leading positions in premium medical products [5] - The company entered into a share purchase agreement to acquire Botanico Ltd., expected to enhance access to premium U.S. genetics and cultivation technologies, with anticipated revenues of over NIS 30 million in the second half of 2026 [5][6] - A strategic investment and collaboration agreement with Cannasoul R&D Ltd. was established, acquiring a 28% stake with an option to increase to 51% within two years, enhancing research and pharmaceutical capabilities [5][6] Regulatory and Market Positioning - The company is closely monitoring regulatory developments in the U.S. regarding cannabis regulations and believes it is well-positioned to benefit from evolving market conditions [5][6] - InterCure's vertically integrated model and international partnerships are expected to drive long-term value for patients and shareholders [6][7]